Why Your Benefits System Can't Handle Early Detection Tests

Every open enrollment season, benefits leaders say the same thing: "Get your screenings. Early detection saves lives and lowers costs."

For traditional screenings-mammograms, colonoscopies, A1C checks-that logic works fine. CPT codes exist. Plan documents are settled. The administrative pathway is smooth.

But there's a revolution happening in early detection, and it's quietly colliding with a structural weakness most employers don't see coming. I'm talking about multi-cancer early detection tests (MCEDs like Grail's Galleri) and continuous biosurveillance wearables.

The usual objections are "too expensive" or "not yet FDA approved." Those are surface-level. The real problem is deeper-and it sits squarely in your benefits administration system, your TPA's claims engine, your stop-loss contract, and your plan document.

Your system is built to pay for claims (events). These tests generate signals (probabilities). That's the impedance mismatch creating a fiduciary and administrative crisis no wellness vendor can fix alone. Here's the sharp breakdown.

1. The Pre-Morbid Black Hole: Where MCED Claims Disappear

Standard claims adjudication follows a binary logic tree:

• Preventive: Free to the member (USPSTF A/B rated).
• Diagnostic: Subject to deductible/coinsurance (requires symptoms).
• Treatment: High cost, medical necessity review.

Where does an MCED test land? Not preventive-the ACA mandate doesn't cover it yet. Not diagnostic-the patient has no symptoms. Most plan documents define medical necessity as "signs or symptoms."

So when the lab sends a claim for a $949 Galleri test, your TPA's engine has no bucket for it. Two outcomes are likely:

1. Auto-deny - "Not a covered preventive service, no symptom to trigger diagnostic."
2. Default to member liability - The employee gets a surprise bill for the "wellness test" your vendor encouraged them to take.

The fiduciary risk: If your wellness program promoted the test and your TPA denied it, the employee has a strong ERISA claim against you, the plan fiduciary. You created a system where no one is liable for failing to process a new class of clinical input.

2. The Stop-Loss Trap: A Million-Dollar Game of "Date of Occurrence"

Self-funded employers often think: "If we pay $1,000 to find one late-stage cancer early, we save $300,000 in chemo. Easy ROI."

Clinically, you're right. Financially, you may be wrong-because of how your stop-loss contract interprets the data.

Consider this scenario:

1. Your plan covers an MCED test (or an employee pays out-of-pocket).
2. The test returns "Signal Detected" for pancreatic cancer.
3. The employee undergoes a six-month diagnostic odyssey to locate the tiny tumor.
4. At month seven, cancer is confirmed. Treatment begins. The claim hits $1M-your stop-loss attachment point.
5. The stop-loss carrier audits the claim and sees the signal date in the lab data feed.

The trap: Many modern stop-loss contracts define the "occurrence" as the date the insured person knew or should have known of the condition. The carrier will argue the occurrence is the MCED signal date, not the clinical diagnosis date.

If your policy has an "incurred expense" clause requiring treatment to start within the policy year, or a "known condition" exclusion at renewal, you've just self-funded a million-dollar claim. Your system processed the test as a wellness screen; the carrier reclassified it as a pre-existing trigger.

Bottom line: You're marketing an early detection tool clinically, but your risk transfer system is legally designed to reject it retroactively.

3. Continuous Monitoring vs. Episodic Care: The Design Gap

Your entire benefits ecosystem is built for episodic care:

• Enrollment event → join the plan.
• Occurrence event → get sick.
• Claim event → get treatment.

Early detection changes the paradigm to continuous monitoring.

Think about a wearable biosensor that detects atrial fibrillation or blood pressure variability before a stroke happens. The wearable generates a clinical signal. The biometric screening vendor captures it. The wellness platform records "completion." But the claims system has no trigger-the employee isn't "sick" yet.

If the employee ignores the signal (because the plan doesn't assign a care coordinator or a path of action), and they have a stroke two months later, your plan has failed.

The system has no concept of a "pre-morbid claimant."

• FMLA/STD: You can't trigger intermittent leave for "investigating a biomarker signal."
• Pharmacy: No formulary pathway for "prophylactic treatment of a high-probability liquid biopsy result."
• Network: No "Signal Navigator" benefit code.

You're paying for the signal but have no administrative pathway to act on it.

How to Fix the System: The Actionable Playbook

This is not a problem for your clinical wellness vendor. It's a benefits administration system design problem. Here are the three fixes.

1. The Plan Document Amendment (The "Signal Rider")

Write explicit language into your self-funded plan document defining "Covered Early Detection Signals."

• State that a positive MCED result triggers Diagnostic Acceleration Coverage-100% coverage of all necessary PET scans, endoscopies, and biopsies for 90 days, regardless of symptoms.
• Contractually override your TPA's default medical necessity logic for this specific use case.

2. The Stop-Loss Reset

Get a Letter of Agreement from your stop-loss carrier stating explicitly:

• The "occurrence date" for a late-stage cancer is the date of pathological confirmation, not the date of the screening signal.
• The MCED signal does not constitute a "known condition" for the purposes of a new policy year or a specific employee exclusion (lasering).

3. The Data Triad Architecture

Your HR/benefits tech stack must move from a duad to a triad:

• Duad: Enrollment data ↔ Claims data.
• Triad: Enrollment data ↔ Signal data (from wellness/lab) ↔ Claims data.

This architecture allows the system to flag a high-probability signal and automatically trigger a care navigation workflow before the claim arrives. It prevents the million-dollar stroke and the ERISA lawsuit simultaneously.

The Bottom Line

The wellness industry is selling you a Ferrari (MCEDs, wearables, biosurveillance). Your benefits administration system is a horse-drawn carriage (claims logic, plan docs, stop-loss contracts).

Until you fix the impedance mismatch between the signal and the claim, you are not offering early detection. You are offering a sophisticated trap for your employees, your budget, and your fiduciary duty.

The early detection revolution will not succeed because of better science. It will succeed because of better benefits systems that know how to handle a probability before it becomes a loss.